A recent study tested an intensive weight loss program in a large group of psychiatric patients. The results were…well, read on and you decide whether they were impressive.

After reading these articles, you should be able to…

With nine other atypical antipsychotics already on the market (some of which are available as generics), did we really need another one? Given the pesky side effects of antipsychotics, maybe we did. Let’s take a look at what we know so far about Latuda (lurasidone) in an effort to figure out how to incorporate it into our clinical toolbox. Latuda was first approved by the US Food and Drug Administration (FDA) for use in schizophrenia in late 2010.

Learn about the new emphasis on community functioning for patients with schizophrenia, in an interview with Dost Ongur, MD, PhD, chief of the psychotic disorders division at McLean Hospital and an associate professor of psychiatry at Harvard Medical School.

We’ve known for some time that if your patient has a parental history of a mood disorder or suicide attempt, his or her risk of a suicide attempt increases, and a new study adds some more information that might help us prevent bad outcomes.

In December 2014, the US Food and Drug Administration (FDA) issued a safety announcement warning that the antipsychotic drug ziprasidone (Geodon) has been associated with a rare but potentially fatal skin reaction.

There’s a new drug in the arsenal to fight obesity.

After reading these articles, you should be able to…

Do you use email to communicate with your patients? Chances are good that you don’t.

Get some practical advice on how to assess a patient’s suicide risk and document your care to help protect against a malpractice lawsuit, in an interview with William H. Reid, MD, MPH, a clinical professor of psychiatry at Texas Tech University Health Sciences Center.